Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening

• Published in: Antiviral research Vol. 199; p. 105268
• Main Authors: Tanaka, Tomohisa, Saito, Akatsuki, Suzuki, Tatsuya, Miyamoto, Yoichi, Takayama, Kazuo, Okamoto, Toru, Moriishi, Kohji
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2022
• Subjects: Antiviral; Antiviral Agents - pharmacology; COVID-19; High-Throughput Screening Assays; Humans; Replicon; SARS-Coronavirus-2; SARS-CoV-2 - genetics; Stable cell line; Virus Replication; SARS-Coronavirus-2; BAC; The replicon-BAC vector; CPER; DMSO; DAPI; nsp; CMV; N; COVID-19; IFN; SARS-CoV-2; UTR; TRS; sgRNA; RdRp; Antiviral; BSL; CMVp; GAPDH; Stable cell line; Replicon
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2022.105268

Experiments with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are limited by the need for biosafety level 3 (BSL3) conditions. A SARS-CoV-2 replicon system rather than an in vitro infection system is suitable for antiviral screening since it can be handled under BSL2 conditions and does not produce infectious particles. However, the reported replicon systems are cumbersome because of the need for transient transfection in each assay. In this study, we constructed a bacterial artificial chromosome vector (the replicon-BAC vector) including the SARS-CoV-2 replicon and a fusion gene encoding Renilla luciferase and neomycin phosphotransferase II, examined the antiviral effects of several known compounds, and then established a cell line stably harboring the replicon-BAC vector. Several cell lines transiently transfected with the replicon-BAC vector produced subgenomic replicon RNAs (sgRNAs) and viral proteins, and exhibited luciferase activity. In the transient replicon system, treatment with remdesivir or interferon-β but not with camostat or favipiravir suppressed the production of viral agents and luciferase, indicating that luciferase activity corresponds to viral replication. VeroE6/Rep3, a stable replicon cell line based on VeroE6 cells, was successfully established and continuously produced viral proteins, sgRNAs and luciferase, and their production was suppressed by treatment with remdesivir or interferon-β. Molnupiravir, a novel coronavirus RdRp inhibitor, inhibited viral replication more potently in VeroE6/Rep3 cells than in VeroE6-based transient replicon cells. In summary, our stable replicon system will be a powerful tool for the identification of SARS-CoV-2 antivirals through high-throughput screening. •The cell line harboring SARS-coronavirus-2 subgenomic replicon were stably established in the presence of G418.•Replication of the replicon in the cell line can be assessed by luciferase activity under a BSL-2 condition.•Treatment with remdesivir, interferon-β, or molnupiravir inhibited replication of the replicon.•This stable replicon system will potently promote the identification of SARS-CoV-2 antivirals by high-throughput screening.